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BACKGROUND: Cholangiocarcinoma (CC) is a highly malignant carcinoma. We attempted to clarify the prognostic significance of c-Met
overexpression and its association with clinicopathological factors in patients with CC.
PATIENTS AND METHODS: One hundred and eleven patients with intrahepatic CC (IHCC) and 136 patients with extrahepatic CC
(EHCC) who had undergone curative surgery were divided immunohistologically into c-Met
high and c-Met
low groups.
Clinicopathological factors and outcomes were compared between the groups. c-Met and epidermal growth factor receptor
(EGFR) expression was also examined in 10 CC cell lines.
RESULTS: The positivity of c-Met was 45.0% in IHCC and 68.4% in EHCC; c-Met
high expression was demonstrated in 11.7% of IHCC
and 16.2% of EHCC. c-Met
high expression was significantly correlated with the 5-year survival rate for CC overall (P¼0.0046) and for
IHCC (P¼0.0013), histopathological classification in EHCC, and for EGFR overexpression in both IHCC and EHCC. Coexpression
and coactivation of c-Met and EGFR were also observed in CC cell lines. Multivariate analysis revealed that c-Met
high expression was
an independent predictor of poor overall and disease-free survival in patients with IHCC.
CONCLUSIONS: c-Met overexpression is associated with EGFR expression and is a poor prognostic factor in CC.
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Cholangiocarcinoma (CC) is a highly malignant invasive carcinoma
arising through malignant transformation of cholangiocytes.
Epidemiologic studies have demonstrated that the incidence and
mortality rates of this disease, especially those of intrahepatic CC
(IHCC), are increasing worldwide (Mouzas et al, 2002; Okuda et al,
2002; Blechacz and Gores, 2008; Hezel and Zhu, 2008; Yachimski
and Pratt, 2008; Aljiffry et al, 2009).
It is difficult to diagnose CC at an early stage because of the lack
of clinical symptoms at this point, and most patients have
unresectable disease at clinical presentation. Surgical resection is
the only curative therapy, but among those patients who receive it,
recurrence rates are high (Hezel and Zhu, 2008). To date, no
randomised study has demonstrated any clear survival benefit of a
specific chemotherapeutic regimen for cases of unresectable and
recurrent CC (Aljiffry et al, 2009). Existing phase II data and a
more recent meta-analysis suggest that gemcitabine and gemcita-
bine-based platinum regimens offer a slight advantage over other
regimens (Hezel and Zhu, 2008).
Recently, a new treatment strategy for CC has been proposed, in
the light of better understanding of the molecular mechanisms of
carcinogenesis: it has been proposed that receptor tyrosine kinases
(RTKs), such as epidermal growth factor receptor (EGFR), vascular
epithelial growth factor (VEGF) and c-Met, are promising targets
for treatment of CC (Socoteanu et al, 2008; Yoshikawa et al, 2008).
In a previous report, we have indicated that EGFR and VEGF could
be promising molecules for targeted therapy of CC (Yoshikawa
et al, 2008, 2009).
c-Met, also known as scatter factor, is a high-affinity receptor for
hepatocyte growth factor (HGF). Activation of HGF-c-Met signal-
ling initiates cell invasiveness and triggers metastasis through
direct involvement of tumour angiogenesis (Zhang et al, 2003).
Upon ligand binding, c-Met activates multiple downstream signal
transduction pathways, including the Grb2-Ras-mitogen-activated
protein kinase (MAPK) cascade, the phosphatidylinositol-3 kinase
(PI3K) pathway, and the signal transducer and activator of trans-
cription (STAT) pathway (Weidner et al, 1993; Furge et al, 2000).
c-Met partners include the integrin a6b4, CD44, plexin B, Fas and
other RTKs such as RON, EGFR and ErbB2 (Gentile et al, 2008).
c-Met and EGFR are considered to assemble oncogenic
signalling networks. Amplified c-Met activates members of the
EGFR family and, conversely, mutated or amplified EGFR activates
c-Met in vitro (Guo et al, 2008). EGFR is frequently coexpressed
with c-Met in cell lines of lung, head and neck, breast, colon, and
brain tumours (Reznik et al, 2008).
Enhanced expression of c-Met protein has been described in
various solid tumours such as breast cancer (Garcia et al, 2007;
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sEder et al, 2009), oesophageal adenocarcinoma (Herrera et al,
2005), gastric cancer (Drebber et al, 2008; Ji et al, 2008), colon
cancer (Liu et al, 1992), lung cancer (Lutterbach et al, 2007;
Nakamura et al, 2007), ovarian cancer (Sawada et al, 2007), brain
tumour (Kong et al, 2009), hepatocellular carcinoma (Boix et al,
1994; Suzuki et al, 1994), and biliary tract carcinoma (Terada et al,
1998; Hida et al, 1999; Aishima et al, 2002; Nakazawa et al, 2005).
Recently, it has been proposed that c-Met might be a promising
target for treatment of CC (Socoteanu et al, 2008). However, no
study has yet demonstrated its prognostic significance in CC.
To improve our understanding of the clinical significance of
c-Met in CC, the primary aim of this study is to clarify the
frequency of c-Met overexpression. Following with this analysis,
the second aim of this study is to analyse its association with
clinicopathological factors, along with molecular data (EGFR,
HER2, and VEGF expression), in the largest cohort (111 cases of
IHCC and 136 cases of extrahepatic CC (EHCC)) of surgical
specimens of CC. We also examined the expression of c-Met and
EGFR in CC cell lines.
PATIENTS AND METHODS
Patients
A total of 247 patients with CC were examined in the present study.
The patients had undergone surgery and been diagnosed
histologically as having adenocarcinoma of the bile duct, except
for cancer of gallbladder and ampulla of Vater, at the National
Cancer Center Hospital, Tokyo, between February 1990 and July
2005. Patients who had other malignancies or had died within four
weeks after surgery were excluded. Clinical and pathological data
200 m 200 m
Figure 2 A representative case showing coexpression of c-Met (A) and EGFR (B) in adjacent sections of the same tumour. Scale bar indicates 200mm.
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Figure 1 c-Met expression in primary CC cases. (A) c-MET expression was exclusively detected in tumour cells (T), but not in non-cancerous bile duct
epithelium (N). (B–D) Representative IHC pictures of higher magnification of c-Met expression (expression score is 2þ (B), 1þ (C), and 0 (D),
respectively). c-MET is localised in both the cell membrane and cytoplasm of CC cells. Scale bar indicates 1.0mm (A) and 200mm( B–D).
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examine the correlations of c-Met with other RTKs (EGFR, HER2,
or VEGF), qualified cases including previous data for over-
expression of these molecules (Yoshikawa et al, 2008) were
examined.
The studied patients included 168 men and 79 women ranging in
age from 33 to 82 years (median 65 years), who had been observed
for periods ranging from 1.4 to 204.5 months (median 29.8
months). The cases were divided into two groups, IHCC and
EHCC, in accordance with the TNM Classification of Malignant
Tumours (Sobin and Wittekind, 2002) defined by the Union for
International Cancer Control (UICC) and the World Health
Organization Histological Classification of Tumours (Hamilton
and Altonen, 2000). There were 111 cases of IHCC and 136 cases of
EHCC. In this study, peri-hilar EHCC and distal EHCC are
combined as EHCC because it is difficult to categorise EHCC based
on the origin of the cystic duct. Tumour recurrence was defined as
tumour growth in any site of the body after the operation, which
was diagnosed clinically, radiologically, or pathologically, but
mainly by computed tomography and ultrasonography. Only
tumour death was used for analysis. The research protocol was
approved by the Ethics Committee of the National Cancer Center,
Tokyo, Japan. All patients gave written informed consent for
inclusion in this study.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 247 formalin-
fixed, paraffin-embedded tissue sections. Immunohistochemical
staining for c-Met was performed using a polymer-based method
(EnvisionþDual link-system-HRP (Dako, Glostrup, Denmark)).
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Figure 3 Immunoblot analysis of c-Met, phosphorylated-Met pY1234/
1235), EGFR, and phosphorylated EGFR (pY1173) in CC cell lines. MKN45
cell (a human gastric cancer cell) is a positive control of c-Met and
phosphorylated-Met expression (Smolen et al, 2006). b-actin is a loading
control.
Table 1 Comparison of clinicopathological factors between patients
with high and low c-Met expression in IHCC
c-Met
High Low P-value
Gender
Male 7 59 0.7636
Female 6 39
Age
X65 9 48 0.2396
o 65 4 50
Tumour size
X5cm 8 39 0.2430
o5cm 5 52
Macroscopic type
Mass forming 10 83 0.4397
Non-mass forming 3 15
Intrahepatic metastasis
Negative 8 70 0.5229
Positive 5 28
Invasion to hepatic vein
Negative 5 53 0.2496
Positive 8 41
Invasion to portal vein
Negative 1 24 0.2907
Positive 12 73
Lymph node metastasis
Negative 7 57 0.7739
Positive 6 41
Histopathological classification
Well differentiated 4 21 0.5943
Moderately differentiated 8 73
Poorly differentiated 1 4
UICC pT
In situ+1+2a+2b 4 28 40.9999
3+4 9 70
UICC stage
I+II 8 51 0.5680
III+IVA 5 47
Lymphatic vessel invasion
Negative 2 37 40.9999
Positive 11 61
Venous invasion
Negative 1 19 0.4566
Positive 12 79
Perineural invasion
Negative 4 27 0.7536
Positive 9 71
Hepatic surgical margin
Negative 9 84 0.2202
Positive 4 14
Bile duct margin
Negative 10 86 0.3797
Positive 3 12
EGFR expression
Negative 5 72 0.0063
Positive 8 21
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embedded serial tissue slices were prepared on silicone-coated
slides for IHC evaluation. Sections cut through the maximum
tumour diameter were selected for IHC evaluation. The sections
were deparaffinised in xylene, and rehydrated through graded
concentrations of ethanol (50–100%). Endogenous peroxidase
activity was blocked by incubation in 0.3% hydrogen peroxide
solution for 30min. The antigens were retrieved by heating in a
pressure cooker at 1211C for 10min in 0.01M citrate buffer. The
tissue sections were incubated overnight at 41C with anti-c-Met
primary antibody (rabbit polyclonal; IBL, Gunma, Japan) at a
dilution of 1:50. After a washing in PBS, the sections were treated
with Envisonþ Dual link reagent at room temperature for 30min.
3,30-Diaminobenzidine tetrahydrochloride was used as the chro-
mogen, and the tissue sections were counterstained with
haematoxylin.
Intensities of c-Met immunoreactivity were defined as: 0,
complete absence of membrane staining or membrane staining
in less than 30% of cancer cells; 1þ, faint and partial membrane
staining in at least 30% of cancer cells; 2þ, strong and complete
staining in at least 30% of cancer cells. The cases were divided into
two groups, c-Met
low (0 or 1þ) or c-Met
high (2þ), for purposes of
statistical analysis. The sections were evaluated by three observers,
MM, HO, and TS, without knowledge of the clinical data. HO and
TS are board-certified pathologists. IHC of EGFR and assessment
of its expression were done as described previously (Yoshikawa
et al, 2008).
Cell lines
NCC-CC1, NCC-CC3-1, NCC-CC3-2, and NCC-CC4 cells were
established from human IHCC, and NCC-BD1and NCC-BD2 from
human EHCC, at the National Cancer Center Research Institute
(Ojima et al, 2010). TKKK, HuCCT1, OZ, TGBC24TKB, and
MKN45 were purchased from RIKEN Bio Resource Center or from
the Japanese Collection of Research Bioresources. TKKK,
TGBC24TKB, and HuCCT1 were established from IHCC, and OZ
was from EHCC. MKN45 was a gastric cancer cell line that was
used as a positive control, because of its high expression of c-Met
and phospho-Met (Smolen et al, 2006). All of the cell lines had
been derived from Japanese patients. The originally established six
CC cell lines, HuCCT1 and MKN45 were maintained in RPMI with
10% bovine serum. TGBC24TKB, TKKK, and OZ were maintained
in Dulbecco’s modified Eagle medium with 10% bovine serum.
Western blotting
Subconfluent cells were lysed at 41C for 30min using lysis buffer
containing 10mM Tris-HCl (pH 7.5), 1% Triton X-100, and 150mM
NaCl with a complete protease inhibitor cocktail (Roche, Basel,
Switzerland) and a phosphate inhibitor cocktail (Nacalai Tesque,
Kyoto, Japan). The protein concentration was determined using a
Table 1 (Continued)
c-Met
High Low P-value
VEGF expression
Negative 7 51 0.5697
Positive 6 42
HER2 expression
Negative 13 92 40.9999
Positive 0 1
Abbreviations: EGFR¼epidermal growth factor receptor; IHCC¼intrahepatic CC;
UICC¼Union for International Cancer Control; VEGF¼vascular epithelial growth
factor.
Table 2 Comparison of clinicopathological factors between patients
with high and low c-Met expression in EHCC
c-Met
High Low 4P-value
Gender
Male 16 86 0.7914
Female 6 28
Age
X65 16 59 0.1004
o65 6 55
Tumour size
X3cm 11 63 0.8144
o3cm 10 50
Macroscopic type
Polypoid 3 19 40.9999
Non-polypoid 18 91
Depth of tumour invasion
Within fm 2 13 40.9999
Beyond fm 20 101
Invasion to hepatic artery
Negative 21 111 0.5106
Positive 1 3
Invasion to portal vein
Negative 20 82 0.0649
Positive 2 32
Lymph node metastasis
Negative 10 65 0.3554
Positive 12 49
Histopathological classification
Papillary 4 18 0.0239
Well differentiated 2 30
Moderately differentiated 9 55
Poorly differentiated 7 11
Lymphatic vessel invasion
Negative 2 98 0.7369
Positive 20 16
Venous invasion
Negative 3 18 40.9999
Positive 19 96
Perineural invasion
Negative 4 21 40.9999
Positive 18 93
Dissected periductal structures margin
Negative 18 97 0.7480
Positive 4 17
Bile duct margin
Negative 16 82 40.9999
Positive 6 32
Invasion to other organ
Negative 12 44 0.2363
Positive 10 70
EGFR expression
Negative 12 93 0.0056
Positive 9 16
VEGF expression
Negative 7 46 0.4798
Positive 14 63
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USA). Lysates (5mg protein per well) were separated by SDS-
PAGE, then transferred to polyvinylidene difluoride membranes
(Millipore, Billerica, MA, USA). The membranes were blocked with
5% skim milk in PBS for 30min and then probed with the
following primary antibodies: anti-c-Met (rabbit polyclonal; IBL;
1:1000), anti-phospho-Met (pY1234/1235, rabbit monoclonal,
clone D26; Cell Signaling Technology, Danvers, MA, USA;
1:1000), anti-EGFR (mouse monoclonal, clone 31G7; Zymed,
South San Francisco, CA, USA; 1:1000), and anti-phospho EGFR
(pY1173, rabbit monoclonal, clone 53A5; Cell Signaling Technol-
ogy) at 41C overnight. After washing with PBS-Tween 20 (0.5%),
the membranes were re-blocked and then incubated at room
temperature for 1h with horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit antibody at a dilution of 1:1000.
Following three washes, bands were visualised using the ECL
Western Blotting Detection Reagents (GE Healthcare UK Ltd,
Buckinghamshire, England). Anti-b-actin (mouse monoclonal;
clone AC-15, Sigma, St Louis, MO, USA) was used as a loading
control.
Statistics
Correlations between the results of IHC and clinicopathological
factors were determined by Fisher’s exact probability test, except
for histopathological classification, which was analysed by w
2-test.
Cumulative survival rates and survival curves were calculated by
the Kaplan–Meier method, and log-rank test was performed for
the comparison of survival curves between low and high groups
defied by c-Met expression level. The Cox proportional hazards
model was used to estimate the hazard ratio and 95% confidence
interval of each outcome (tumour death and recurrence). Multi-
variate analysis was performed for factors selected as risk factors
by univariate analysis, except for UICC pT and UICC stage, which
are composed of other factors. Correlations between the intensity
of c-Met and that of EGFR in IHC or Western blotting were
determined by Spearman’s rank correlation. Statistical analysis
was done using the Statview 5.0 statistical software package
(Abacus Concepts, Berkeley, CA, USA). The level of significance
was set at Po0.05.
RESULTS
Immunohistochemical analysis of c-Met in human
CC specimens
c-Met staining was localised in both the cell membrane and
cytoplasm of CC cells (Figure 1). Strong immunostaining for c-Met
was apparent at the luminal cell surface of neoplastic glands and
ducts of adenocarcinoma. Positive staining for c-Met was
demonstrated in 143 (57.9%, 95% CI: 51.7–64.1) of the 247 cases
of CC overall, 50 (45.0%, 95% CI: 35.7–54.3) of the 111 cases of
IHCC, and 93 (68.4%, 95% CI: 60.6–76.2) of the 136 cases of
EHCC; high c-Met expression (2þ) was demonstrated in 35
(14.2%, 95% CI: 9.8–18.6) of the 247 cases of CC overall, 13
(11.7%, 95% CI: 5.7–17.7) of the 111 cases of IHCC, and 22 (16.2%,
95% CI: 10.0–22.4) of the 136 cases of EHCC. When compared
with EGFR staining, we occasionally observed coexpression of
c-Met and EGFR (Figure 2).
c-Met and EGFR expression in CC cell lines
Expression of c-Met, phospho-Met, EGFR, and phospho-EGFR
in ten CC cells and one gastric cancer cells were estimated by
Table 2 (Continued)
c-Met
High Low 4P-value
HER2 expression
Negative 19 100 40.9999
Positive 2 9
Abbreviations: EGFR¼epidermal growth factor receptor; EHCC¼extrahepatic CC;
fm¼fibromuscular layer; VEGF¼vascular epithelial growth factor.
1
A
B
C
0.8
Total CC
IHCC
5-year survival
5-year survival
c-metlow 43.6%
31.4%
P=0.0046
c-methigh
c-metlow 41.1%
15.4%
P=0.0013
c-methigh
EHCC
5-year survival
c-metlow 45.8%
40.9%
P=0.1396
c-methigh
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Figure 4 Survival curves according to c-Met expression. High c-Met
expression was significantly correlated with poor survival in patients with
CC as a whole (A) and in those with intrahepatic CC (IHCC) (B), but not
in those with extrahepatic CC (EHCC) (C).
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nine CC cells. Coexpression of c-Met and EGFR was detected in
eight of them (except NCC-CC3-1). Prominent c-Met phosphor-
ylation was detected in five cell lines (HuCCT1, OZ, NCC-BD2,
TGBC24TKB, and NCC-BD1) and simultaneous activation of c-Met
and EGFR was observed in seven cell lines including these five.
Correlations between c-Met and clinicopathological factors
The relationships between c-Met expression and clinicopatho-
logical factors of IHCC and EHCC were evaluated and are shown in
Tables 1 and 2. Increased expression of c-Met was significantly
correlated with overexpression of EGFR in IHCC (P¼0.0063), and
histopathological classification (P¼0.0239) and overexpression of
EGFR (P¼0.0056) in EHCC. No other clinical factors were
associated with c-Met expression.
Five-year survival for patients in the c-Met
high and c-Met
low
groups was 15.4 and 41.1% (P¼0.0013) for IHCC and 40.9 and
45.8% (P¼0.1396) for EHCC, respectively (Figure 4). We then
performed multivariate analysis to assess the prognostic signifi-
cance of c-Met expression. In IHCC, the independent predictors of
poor overall survival were high c-Met expression (HR:3.92, 95%
CI:1.62–9.48), macroscopic type (HR:4.57, 95% CI:1.44–14.51),
intrahepatic metastasis (HR:3.27, 95% CI:1.78–5.99), and lymph
node metastasis (HR:1.99, 95% CI:1.11–3.59). High c-Met expres-
sion (HR:3.50, 95% CI:1.56–7.85), macroscopic type (HR:4.78, 95%
CI:1.69–13.4), intrahepatic metastasis (HR:2.78, 95% CI:1.60–
4.82), lymph node metastasis (HR:2.94, 95% CI:1.70–5.08), venous
invasion (HR:4.62, 95% CI:1.13–18.8), and EGFR overexpression
(HR:1.98, 95% CI:1.12–3.51) were significant predictors of disease-
free survival (Table 3).
In EHCC, the c-Met
high group tended to have a poor
5-year survival rate, but not to a significant degree.
Univariate analysis also showed that c-Met
high was not a significant
factor for survival. Therefore, multivariate analysis was
not performed for EHCC.
Table 3 Multivariate analyses of overall survival and disease-free survival in patients with IHCC. (Cox proportional hazards model)
Overall survival Disease-free survival
HR 95% CI P-value HR 95% CI P-value
Macroscopic type
Mass forming 4.572 1.440–14.516 0.0099 4.783 1.698–13.470 0.0030
Non-mass forming 1.00 1.00
Intrahepatic metastasis
Negative 1.00 1.00
Positive 3.270 1.783–5.999 0.0001 2.781 1.604–4.822 0.0003
Invasion to portal vein
Negative 1.00 —
Positive 0.881 0.388–1.999 0.7623 — — —
Lymph node metastasis
Negative 1.00 1.00
Positive 1.998 1.110–3.597 0.0209 2.947 1.707–5.088 0.0001
Histopathological classification
Well differentiated 1.00 1.00
Moderately differentiated 1.507 0.639–3.554 0.3491 0.753 0.345–1.642 0.4759
Poorly differentiated 2.031 0.526–7.835 0.3036 1.199 0.340–4.227 0.7772
Lymphatic vessel invasion
Negative 1.00 1.00
Positive 3.119 0.851–11.435 0.0860 2.723 0.759–9.768 0.1243
Venous invasion
Negative 1.00 1.00
Positive 3.121 0.825–11.807 0.0935 4.628 1.136–18.854 0.325
Perineural invasion
Negative 1.00 1.00
Positive 0.588 0.265–1.305 0.1917 0.511 0.244–1.072 0.756
Bile duct margin
Negative 1.00 —
Positive 1.871 0.902–3.882 0.0926 — — —
EGFR expression
Negative 1.00 1.00
Positive 1.745 0.957–3.180 0.0690 1.987 1.125–3.511 0.0180
c-Met expression
Negative 1.00 1.00
Positive 3.921 1.620–9.487 0.0003 3.502 1.562–7.851 0.0023
Abbreviations: CI¼Confidence interval; EGFR¼epidermal growth factor receptor; HR¼Hazard ratio; IHCC¼intrahepatic CC.
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sDISCUSSION
In the present study, we have demonstrated the importance of
c-Met overexpression in the prognosis and treatment of CC. We
found that c-Met expression was correlated with EGFR over-
expression in CC, and that it was also a significant prognostic
factor in IHCC. In previous studies, the frequency of c-Met
overexpression ranged from 21 to 58% in IHCC (Terada et al, 1998;
Aishima et al, 2002; Nakazawa et al, 2005) and from 0 to 80% in
EHCC (Hida et al, 1999; Nakazawa et al, 2005). This rather broad
range is probably attributable to the small numbers of cases
studied, or to differences in the definition of positivity. Moreover,
no correlation between c-Met overexpression and clinical outcome
of CC has been demonstrated previously. Here we showed that
increased expression of c-Met was significantly associated with
decreased overall and disease-free survival in patients with IHCC.
The reason why c-Met expression was not a prognostic factor in
EHCC may be partly explained by variables associated with their
anatomic behaviour and methods of surgery.
Simultaneous expression of c-Met and EGFR has been observed
in clinical specimens of primary chordoma (Weinberger et al,
2005) and gastrinoma (Peghini et al, 2002). Accumulated evidence
has suggested that cross-talk occurs between c-Met and EGFR in
several cancer cell lines (Jo et al, 2000; Farazi et al, 2006; Guo et al,
2008). Here we showed that c-Met expression was correlated with
EGFR expression in clinical specimen of CC. We found that both
EGFR and c-Met are broadly activated in CC cell lines. Eight CC
cells coexpressed both c-Met and EGFR and coactivation of both
proteins was detected in seven CC cell lines. It has been proposed
that amplified c-Met drives the activity of EGFR family members
and that mutated and amplified EGFR can drive c-Met activity
(Guo et al, 2008). Mutual or unidirectional interaction between
EGFR and MET activation has been reported in several cell lines
(Bergstrom et al, 2000; Jo et al, 2000; Reznik et al, 2008). It is
thought that either c-Met or EGFR stands at the top of the
hierarchy of the downstream signalling pathway governed by the
two molecules in a subset of cancer.
Collectively, it seems reasonable that efficient molecular therapy
for CC should target multiple kinases such as c-Met, EGFR, and
VEGFR. c-Met activation is regarded as one of the molecular
mechanisms involved in the acquisition of resistance to anti-EGFR
therapy, as activation of the alternative RTK pathway would bypass
the EGFR pathway (Dempke and Heinemann, 2009). Therefore,
inhibition of c-Met, either alone or in combination with an EGFR
inhibitor, may be clinically beneficial in the setting of EGFR
inhibitor resistance (Eder et al, 2009). Several studies have focused
on combination therapy with c-Met inhibitors and agents targeting
EGFR family members (Toschi and Janne, 2008).
In conclusion, c-Met overexpression is significantly correlated
with overexpression of EGFR in CC and with prognosis in IHCC.
Further molecular investigation of the interaction between EGFR
and c-Met in this fatal disease is urgently needed.
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